Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 337 with mFOLFOX6 in Advanced Gastric and Esophageal Adenocarcinoma
NCT02344810Phase 2Withdrawn
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Mar 2015
- Primary completion
- Mar 2015
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of AMG-337 in gastric adenocarcinoma, esophageal adenocarcinoma (EAC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoints: Maximum Tolerated Dose at 28 days and Progression-Free Survival at 2 years. Planned start Mar 2015; status: withdrawn.
02
Drugs
AMG-337
03
Conditions
gastric adenocarcinomaesophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02344810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02344810.